Clinical Trial

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-02
notable Trial sites expanded: 1 -> 8 locations 2026-07-02
Trial Details
NCT Number NCT07516132
Lead Sponsor Ocular Therapeutix, Inc.
Collaborators: Fortrea, Duke Reading Center
Conditions Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment 850 participants
Start Date 2026-04-27
Primary Completion 2030-08-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-01